FDA declines to approve novel MDMA therapy to treat PTSD, with request for more trial dataFDA declines to approve novel MDMA therapy to treat PTSD, with request for more trial data 

The US Food and Drug Administration has declined to approve an application for the use of MDMA, commonly known as ecstasy, as a treatment for post-traumatic stress disorder, according to a news release from drug sponsor Lykos Therapeutics. The company says the agency has requested an “additional Phase 3 trial to further study the safety and efficacy” of the treatment.